DHR · News · 20261103N

Rapid Infection Diagnostic Assay

DANAHER CORP /DE/ · 2026-11-03 · Importance 41 · Surprise 60

Beckman Coulter Diagnostics received U.S. FDA clearance for the Access MeMed BV assay, a host-response blood test that distinguishes bacterial from viral infections in adults and children. The assay runs on installed DxI 9000 and Access 2 immunoassay analyzers, requiring no new instrumentation or workflow changes. On the DxI 9000, results are available in as little as 15 minutes, positioning the product for hospital laboratories seeking rapid infection diagnostics.

Key facts

• Danaher sponsored a World Sepsis Congress satellite session scheduled for November 4, focused on precision diagnostics to improve sepsis outcomes. source
• The Access MeMed BV assay is available on the DxI 9000 and Access 2 immunoassay analyzers already installed in hospital laboratories nationwide, without requiring new instrumentation or changes to existing testing workflows. source
• The Access MeMed BV assay is a rapid host-response blood test that helps clinicians distinguish bacterial from viral infections in adult and pediatric patients. source
• On the DxI 9000 Analyzer, the Access MeMed BV assay provides results in as little as 15 minutes. source